ABSTRACT
INTRODUCTION

Aim
The aim of this study was to describe the clinical and ultrasound characteristics of pure endometrioid ovarian carcinomas.
Background
Epidemiology
Endometrioid carcinoma accounts for 10-15% of ovarian epithelial carcinomas, representing the second most common type of ovarian epithelial cancer 1 . This tumor is most often diagnosed in the fifth and sixth decades of life, and the mean age at presentation is 55-58 years, slightly earlier than the age at which the most common type of epithelial cancer, serous carcinoma, is diagnosed 2 . A substantial proportion (10-50%) of ovarian endometrioid carcinomas develop from endometriosis 3 . The association between endometriosis and ovarian cancer was first described by Sampson in 1925 4 . He developed strict criteria to define malignant transformation of endometriosis: endometriosis being close to the tumor; malignant foci arising in endometrioid lesions rather than originating outside these lesions; and the presence of tissue resembling endometrial stroma surrounding the characteristic glands. Scott 5 added a fourth criterion: histologically proven transition from benign endometriosis to cancer. However, Fukunaga et al. 6 , in a case series of 224 malignant epithelial tumors, found that 54 of them manifested evidence of tumor developing from endometriosis according to the Sampson and/or Scott criteria, but only 13/54 (24.1%) showed a true transitional area from endometriosis to a malignant epithelial tumor.
It has been reported that 15-20% of endometrioid carcinomas in the ovary coexist with endometrial carcinoma 1 . In these cases, usually both the ovarian and endometrial tumors are well differentiated and resemble each other. The criteria for distinguishing metastatic from independent primary ovarian carcinomas rely mainly on clinicopathological findings. In cases of low-grade endometrial carcinoma associated with hyperplasia and minimal or no myometrial invasion, the ovarian tumor can be regarded as an independent primary tumor, particularly if endometriosis is also present. Bilaterality, multinodular growth, vascular space invasion and tubal invasion are characteristics of ovarian metastasis of endometrial cancer 1 . According to the dualistic model of epithelial ovarian carcinogenesis 7 , endometrioid carcinoma is a Type-I tumor. Type-I tumors appear to develop from well-established precursor lesions (such as endometriosis for endometrioid and clear-cell carcinomas). These may undergo malignant transformation in a slow stepwise fashion. In contrast, Type-II tumors (i.e. high-grade serous carcinomas) develop from intraepithelial carcinomas in the Fallopian tube that disseminate into the ovary and extraovarian sites, and have an aggressive behavior.
Microscopy
Endometrioid adenocarcinoma is characterized classically by confluent glandular epithelial proliferation exceeding the limit for microinvasion (5 mm). This pattern is typically characterized by extensive glandular branching, budding, true cribriform architecture and highly complex papillary proliferations. Less frequently, a destructive infiltrative pattern is seen 1 .
Most ovarian endometrioid carcinomas are well differentiated and show low-grade (i.e. Grade-1 and Grade-2) nuclei. Poorly differentiated endometrioid carcinomas are predominantly solid with focal microglandular areas. The grade of endometrioid carcinoma is determined by the microscopic appearance of the tumor, and is based on both its architectural pattern and its nuclear features 1 . The architectural grade is determined by the extent to which the tumor is composed of solid masses of cells as compared with well-defined glands: Grade 1 when no more than 5% of the tumor is composed of solid masses, Grade 2 when 6-50% of the tumor is composed of solid masses and Grade 3 when more than 50% of the tumor is composed of solid masses. The nuclear grade is determined by nuclear size and shape, chromatin distribution and size of the nucleoli. Grade-1 nuclei are oval, mildly enlarged and have evenly dispersed chromatin; Grade-3 nuclei are markedly enlarged and pleomorphic, with irregular coarse chromatin and prominent eosinophilic nucleoli; Grade-2 nuclei have features intermediate between those of Grades 1 and 3.
These microscopic features are typical of pure endometrioid carcinoma, which is the most common variant of endometrioid ovarian carinoma 1 . Other variants exist, e.g. endometrioid carcinoma with squamous differentiation (characterized by squamous cells), sertoliform endometrioid carcinomas, endometrioid carcinomas resembling sex cord-stromal tumor, endometrioid carcinoma with an undifferentiated neuroendocrine component and endometrioid carcinoma mixed with clear-cell carcinoma 1, 8 .
Macroscopy
Endometrioid carcinomas have a mean size of 15 cm and have a smooth outer surface. They are unilateral in 83-87% of cases 1, 8 . The cut surface can display friable soft masses or papillae partly filling cystic spaces that contain blood-stained fluid 1 . They can also be completely solid, exhibiting hemorrhage or necrosis. Tumors developing from endometriosis may display gross findings of an endometriotic cyst containing chocolate-colored fluid with one or more solid nodules or papillary excrescences protruding from the wall 1 .
Clinical features and prognosis
The most common symptoms of endometrioid carcinomas are pelvic pain and abdominal distension, but abnormal vaginal bleeding is also frequent because of the association of ovarian endometrioid carcinoma with endometrial hyperplasia with atypia and endometrial carcinoma 1 . Serum CA 125 is elevated in more than 80% of cases 1 . The stage distribution of endometrioid carcinomas differs from that of both low-grade and high-grade serous carcinomas. Most patients with a low-grade or high-grade serous carcinoma present at an advanced stage (Stages III-IV) 9 , whereas approximately 80% of ovarian endometrioid carcinomas present with disease confined to the pelvis (Stages I and II) 10, 11 . Endometrioid carcinoma carries the most favorable prognosis of all ovarian carcinoma histotypes, with a 5-year survival rate of more than 70% if one does not take stage into account. For patients diagnosed at Stage IA/IB/IC1 (IC1 meaning surgical spill only) according to the International Federation of Obstetricians and Gynecologists (FIGO) 2013 staging system 12 , the 5-year survival is about 95%, and those patients do not require adjuvant therapy after surgery 11, 13 .
METHODS
This was a retrospective multicenter study including patients from 11 ultrasound centers (Table 1, Table S1 ). From the International Ovarian Tumor Analysis (IOTA) database, we identified patients with a histological diagnosis of pure endometrioid carcinoma who had undergone preoperative ultrasound examination by an experienced ultrasound examiner between 1999 and 2016 (IOTA study phases 1, 1b, 2, 3 and 5) [14] [15] [16] [17] . Additional patients, investigated outside the IOTA protocol, who received a histological diagnosis of pure endometrioid carcinoma between 2007 and 2016 and with ultrasound images available, were identified retrospectively from databases of the departments of gynecological oncology of the participating centers.
All patients were examined preoperatively with transvaginal ultrasound (supplemented with a transabdominal scan, if necessary) using a standardized 18 . All ultrasound examiners had more than 10 years' experience in gynecological ultrasound, and the ultrasound examinations were carried out using high-end equipment. The frequency of the vaginal probes varied between 5.0 and 9.0 MHz and that of the abdominal probes between 3.5 and 5.0 MHz.
For women included in the IOTA studies, clinical and ultrasound information was obtained from the IOTA databases containing prospectively collected data. For patients examined outside the IOTA study protocol, and in case of missing information in the IOTA database, information was retrieved retrospectively from the patients' medical records and entered into an Excel file (Microsoft Office Excel 2007, Redmond, WA, USA) by the principal investigator of each center. Final histology, tumor grade, FIGO stage 12 , presence of a synchronous endometrial cancer and signs of cancer developing from endometriosis, as judged by the local pathologist, were recorded.
In the case of bilateral adnexal masses, the mass with the more complex ultrasound morphology was used in the analysis. If both masses had similar ultrasound morphology, the larger mass or the one more easily accessible by ultrasound was included. The masses were described using the terms and definitions published by the IOTA group 18 . Papillary projections were defined as projections of solid tissue into the cystic cavity arising from the cyst wall or from a septum with a length of ≥ 3 mm. The largest solid component other than a papillary projection (i.e. a solid component not protruding into the cyst cavity) was also measured. In accordance with the IOTA consensus statement, if a papillary projection was the largest solid component of a mass, the papillary projection was recorded and measured both as a papillary projection and as the largest solid component 18 . The presence of ascites and fluid in the pouch of Douglas was noted. The vascularization of the tumors on color Doppler was described using the IOTA color score: no detectable blood flow (color score = 1), minimal blood flow (color score = 2), moderate blood flow (color score = 3) or abundant blood flow (color score = 4). The specific diagnosis suggested by the ultrasound examiner in the original ultrasound report was recorded.
In addition to using the information collected in the IOTA database and in the patients' medical records, one author with more than 10 years' experience in gynecological ultrasound (F.M.) assessed available ultrasound images (most of them electronic) of pure ovarian endometrioid carcinomas using pattern recognition with the aim of identifying typical ultrasound patterns 19 . While doing so, the author was blinded to the histological findings (tumor developing from endometriosis or not, presence of a synchronous endometrial cancer or not).
All clinical and ultrasound data were entered into a dedicated Excel file. Results are presented as absolute frequency (percentage) for nominal variables and as median (range) for continuous variables. The Mann-Whitney U-test test for continuous variables and the χ 2 or Fisher's exact test for nominal variables were used as appropriate. Two-sided tests were used and the significance level was set at P < 0.05. Statistical analysis was performed using the Statistical Package for the Social Sciences software (SPSS Statistic, IBM corp., New York, NY, USA, PASW version 20.0).
RESULTS
We identified 161 patients from the IOTA databases and another 78 examined outside the IOTA studies who had a diagnosis of pure endometrioid cancer. There were no substantial differences in clinical or ultrasound characteristics between cases examined inside and those examined outside the IOTA studies (Tables S1 and S2) , therefore results are presented together for all 239 cases. Demographic background data and tumor characteristics of all patients are shown in Table 1 Table 2 . Most tumors (188 (78.7%)) were unilateral, and median largest diameter was 102.5 mm (range, 20-300 mm). Almost all endometrioid carcinomas were described as unilocular-solid (37 (15.5%)), multilocular-solid (115 (48.1%)) or solid masses (82 (34.3%)), and the median largest diameter of the largest solid component was 63 mm (range, 9-300 mm). Papillary projections were seen in 70 (29.3%) masses and most of those masses contained more than three papillary projections, the median height of the largest papillary projection being 16 mm (range, 4-64 mm). The most common echogenicity of cyst fluid was low-level echogenicity (83/157 (52.9%)). Ground-glass echogenicity was uncommon (25/157 (15.9%)). All but three tumors were vascularized at color Doppler examination, and most (186/238 (78.2%)) had a color score of 3 or 4. On the basis of subjective assessment by the original ultrasound examiner, 202 (84.5%) masses were classified as malignant, 27 (11.3%) as borderline tumors and 10 (4.2%) as benign tumors. Four of the 10 tumors misdiagnosed as benign masses by the original examiner were suspected to be fibromas/fibrothecomas, two to be endometriomas, two to be hydrosalpinx/pelvic inflammatory disease, one to be a cystadenoma and one to be a dermoid cyst. Ultrasound images were available for eight of the 10 misclassified cancers ( Figure S1 ).
In 49/239 (20.5%) patients, the pathologist judged the cancer to develop from endometriosis, and 11/46 (23.9%) of these patients also had synchronous endometrial cancer, whereas information on synchronous endometrial cancer was lacking in three of them. Of the 190 patients with a tumor with no evidence of the cancer developing from endometriosis, 30/179 (16.8%) also had synchronous endometrial cancer, while information on synchronous endometrial cancer was lacking in 11 of them. Patients with cancer developing from endometriosis had lower median serum CA 125 levels than did those without evidence of cancer developing from endometriosis (64 U/mL vs 256.5 U/mL), and the cancers developing from endometriosis were more often Stage I (81.6% (40/49) vs 52.4% (99/189)) and Grade 1 (34.7% (17/49) vs 23.5% (40/170)) ( Table 1 ). Ultrasound characteristics of endometrioid cancers according to whether there was evidence of it developing from endometriosis are shown in Table 2 The small sample size precluded a reliable estimation of differences in clinical background data or ultrasound features between endometrioid cancers developing from endometriosis with, vs those without, a synchronous endometrial cancer, and between endometrioid cancers not developing from endometriosis with, and those without, a synchronous endometrial cancer (Tables S3, S4 and Figure S2 ). No obvious differences were seen in ultrasound appearance. However, patients with endometrioid ovarian cancers not developing from endometriosis with a synchronous endometrial cancer were younger and more often nulliparous than those without a synchronous endometrial cancer. CA 125 values seemed to be lowest in women with cancer developing from endometriosis without a synchronous endometrial cancer.
Ultrasound images were available for 66 of the 161 pure ovarian endometrioid carcinomas identified from the IOTA database and for all 78 patients examined outside the IOTA studies, i.e. for 144/239 (60.3%) of all endometrioid cancers included in the Figure 2 Ultrasound images of pure endometrioid carcinomas without evidence of tumor developing from endometriosis on histological examination. Carcinomas were described as multilocular-solid masses (a-g) or solid masses (h,i). Cockade-like appearance is seen in (a-g).
study. On retrospective review of these, 17/31 (54.8%) endometrioid cancers developing from endometriosis were described by the reviewer of the images as cysts with papillary projections (Figure 1) . The most typical (41/113 (36.3%)) ultrasound image of an endometrioid cancer not developing from endometriosis was a cyst with a large central solid component entrapped within locules. This gave the lesion a cockade-like appearance (Figure 2) . Using pattern recognition, no obvious difference was observed between cancers developing from endometriosis with, and those without, synchronous endometrial cancer, and no obvious difference was found between cancers not developing from endometriosis with, vs those without, synchronous endometrial cancer ( Figure S2 ).
DISCUSSION
This study describes the clinical and ultrasound characteristics of pure endometrioid ovarian carcinomas. The median age at diagnosis was 55 years (range, 19-88 years) and most tumors were FIGO Stage I and Grade 1 or 2. On ultrasound, most endometrioid cancers were large, unilateral, multilocular-solid tumors, usually with low-level echogenicity of the cyst fluid, or solid masses. About 20% of the endometrioid cancers developed from endometriosis and approximately 20% were associated with synchronous endometrial cancer. Using pattern recognition, cancers developing from endometriosis were often described as cysts with papillary projections, while carcinomas without evidence of tumor developing from endometriosis were often described as having a large central solid component entrapped within locules, giving the tumor a cockade-like appearance.
The main strength of our study is that it comprises a large series of pure ovarian endometrioid carcinomas described in a standardized manner, but it also has limitations. First, owing to its retrospective nature, some clinical and histological data were missing. Second, we cannot guarantee that all the pathologists involved strictly applied Sampson's criteria to define cancer developing from endometriosis. Third, ultrasound images or videoclips were not available for all cases, and this may have limited our capacity to detect typical ultrasound features.
Our clinical findings agree with those of others in that endometrioid cancers with evidence of tumor developing from endometriosis more often were diagnosed at an early stage and more often were Grade 1 or 2 compared with those with no evidence of tumor developing from endometriosis 20 . We did not find any data in the literature to support directly our finding that patients with endometrioid cancer not developing from endometriosis with synchronous endometrial cancer were substantially younger and more often nulliparous than patients with endometrioid cancer not developing from endometriosis without synchronous endometrial cancer. The finding of Uccella et al. 21 that patients with endometrial cancer and a synchronous ovarian cancer were younger than those with endometrial cancer without a synchronous ovarian cancer, indirectly supports our observations. Our results are in agreement with the macroscopic features of endometrioid cancers reported in textbooks of pathology, in which they are described as unilateral and quite large solid tumors or cysts with solid masses or papillations, and in which endometrioid cancers developing from endometriotic cysts are described as cysts with one or more papillary excrescence(s) protruding from the internal cyst wall 8 . They are also in agreement with those of Testa et al. 22 , who reported that the typical ultrasound appearance of an ovarian cancer developing from endometriosis is a cyst with papillary projections. However, not all cancers in the series of Testa et al. were endometrioid cancers; some were clear-cell cancers and one was a borderline tumor of mucinous endocervical type. In contrast to endometriomas with endometrioid or other epithelial malignancy arising in them, benign ovarian endometriomas typically appear as unilocular or multilocular cysts without solid components, even though their ultrasound appearance may vary slightly with age 23, 24 . In a large series of malignant ovarian tumors including invasive epithelial ovarian cancers of all histotypes, Valentin et al. 25 found a higher proportion of masses with papillations (67% of epithelial ovarian cancers at Stage I and 41% of epithelial ovarian cancers at Stages II-IV) than we did in our series (29.3%), which includes only endometrioid ovarian tumors. The cockade-like appearance of endometrioid cancer has not been described by others. It remains to be shown if this is indeed a specific sign of endometrioid cancer, or if it is also found in other primary epithelial ovarian cancers.
The original ultrasound examiner correctly classified the vast majority of endometrioid ovarian cancers (202/239 (84.5%)) as invasive malignant tumors. Only 10/239 (4.2%) were misdiagnosed as benign. This confirms the high accuracy of ultrasound for discriminating between benign and malignant ovarian masses 26, 27 . However, 27/239 (11.3%) endometrioid cancers were misdiagnosed as borderline tumors. This is probably explicable by the fact that many endometrioid cancers have papillary projections, which are common in serous borderline tumors and in mucinous endocervical-type borderline tumors 28, 29 .
The ultrasound characteristics of endometrioid ovarian cancers differ from those of mucinous and serous ovarian carcinomas described previously 29, 30 (Table  S5) . Whether it is possible to discriminate correctly between different types of ovarian malignancy on the basis of ultrasound images and clinical information can only be determined in a prospective study. However, before starting any prospective study, the typical ultrasound appearance of different types of ovarian malignancy must be known. The typical ultrasound appearance of several different adnexal pathologies, including various types of malignancy, has been described in the 'imaging in gynecological disease' series of this journal [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] (also see Virtual Issue https://obgyn .onlinelibrary.wiley.com/doi/toc/10.1002/(ISSN)1469-0705.IMAGINGINGYNECOLOGICALDISEASE).
Being able to distinguish preoperatively an endometrioid carcinoma from other invasive tumors is of clinical importance because of the favorable prognosis of these tumors, especially those developing from endometriotic cysts. Suspicion of endometrioid cancer and of endometrioid cancer developing from endometrioma may affect preoperative counseling. For example, optimal cytoreduction is likely to be achievable in patients with endometrioid carcinoma because endometrioid cancers are often diagnosed at an early stage 7 . Moreover, in patients who want to preserve their fertility, conservative surgery might be possible for a Stage-I endometrioid cancer developing from an endometriotic cyst, because these tumors seem to have a better prognosis than those not developing from endometriosis 39 .
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Figure S1 Ultrasound images of endometrioid carcinomas misdiagnosed as benign masses by original examiner. One mass was misdiagnosed as a dermoid cyst (a), one as a cystadenoma (b), one as pelvic inflammatory disease (c), one as hydrosalpinx (d), two as endometriomas (e,f) and two as fibromas (g,h).
Figure S2
Ultrasound images of endometrioid carcinoma developing from endometriosis with synchronous endometrial cancer (a), endometrioid carcinoma developing from endometriosis without synchronous endometrial cancer (b), endometrioid carcinoma not developing from endometriosis with synchronous endometrial cancer (c), and endometrioid carcinoma not developing from endometriosis without synchronous endometrial cancer (d).
